By proceeding, I agree that I understand the following disclosures:
I. How We Work in Washington. Based on your preferences, we provide you with information about one or more of our contracted senior living providers ("Participating Communities") and provide your Senior Living Care Information to Participating Communities. The Participating Communities may contact you directly regarding their services. APFM does not endorse or recommend any provider. It is your sole responsibility to select the appropriate care for yourself or your loved one. We work with both you and the Participating Communities in your search. We do not permit our Advisors to have an ownership interest in Participating Communities.
II. How We Are Paid. We do not charge you any fee – we are paid by the Participating Communities. Some Participating Communities pay us a percentage of the first month's standard rate for the rent and care services you select. We invoice these fees after the senior moves in.
III. When We Tour. APFM tours certain Participating Communities in Washington (typically more in metropolitan areas than in rural areas.) During the 12 month period prior to December 31, 2017, we toured 86.2% of Participating Communities with capacity for 20 or more residents.
IV. No Obligation or Commitment. You have no obligation to use or to continue to use our services. Because you pay no fee to us, you will never need to ask for a refund.
V. Complaints. Please contact our Family Feedback Line at (866) 584-7340 or
[email protected] to report any complaint. Consumers have many avenues to address a dispute with any referral service company, including the right to file a complaint with the Attorney General's office at: Consumer Protection Division, 800 5th Avenue, Ste. 2000, Seattle, 98104 or 800-551-4636.
VI. No Waiver of Your Rights. APFM does not (and may not) require or even ask consumers seeking senior housing or care services in Washington State to sign waivers of liability for losses of personal property or injury or to sign waivers of any rights established under law.I agree that: A.I authorize A Place For Mom ("APFM") to collect certain personal and contact detail information, as well as relevant health care information about me or from me about the senior family member or relative I am assisting ("Senior Living Care Information"). B.APFM may provide information to me electronically. My electronic signature on agreements and documents has the same effect as if I signed them in ink. C.APFM may send all communications to me electronically via e-mail or by access to an APFM web site. D.If I want a paper copy, I can print a copy of the Disclosures or download the Disclosures for my records. E.This E-Sign Acknowledgement and Authorization applies to these Disclosures and all future Disclosures related to APFM's services, unless I revoke my authorization. You may revoke this authorization in writing at any time (except where we have already disclosed information before receiving your revocation.) This authorization will expire after one year. F.You consent to APFM's reaching out to you using a phone system than can auto-dial numbers (we miss rotary phones, too!), but this consent is not required to use our service.
*If I am consenting on behalf of someone else, I have the proper authorization to do so. By clicking Get My Results, you agree to our
Privacy Policy. You also consent to receive calls and texts, which may be autodialed, from us and our customer communities. Your consent is not a condition to using our service. Please visit our
Terms of Use. for information about our privacy practices.
ETA. there was a 2008 post on here about Enbrel. It is an interesting read.
The insurance data had a noticeable-but-small signal that, by itself, is not by any stretch of the imagination sufficient for anyone to launch an Alzheimer’s trial.
When was the last time a drug company walked away from big profits? Pfizer knows how to make money and if Pfizer really believed that their drug was a promising lead into treating Alzheimer’s, they would have found some way to turn a profit off of it.
Enbrel doesn’t penetrate the brain; therefore, what is the mechanism of action? The question of whether or not there was something real in the data that was worth pursuing was ultimately answered by both Pfizer and Amgen with a resounding "no".
So far, every single amyloid-antibody trial has ended in abysmal failure. Targeting beta-amyloid is not the pathway to success for which people had hoped.
That Enbrel’s patent is about to expire is being debated in the courts right now.
Enbrel was never an Alzheimer's drug but rather it targeted rheumatoid arthritis and psoriasis. Therefore, any generic/biosimilars would have to demonstrate their own efficacy against Alzheimer’s.
We know that the brains of Alzheimer’s patients show persistent inflammation. It's a chicken/egg problem: does Alzheimer’s lead to inflammation or does inflammation lead to Alzheimer’s. And every single anti-inflammatory therapy - aspirin included - has been looked at for its potential in treating Alzheimer’s and, so far, nothing affects the disease progression.
As a preventative drug, maybe the downside vs. the benefit ratio was too huge to get the FDA involved. Announcing a possible benefit, still unproven, would have the FDA crawling all over your physician's files looking to shut you down, imo.
Allowing the patent (that word it PATENT, not patient) to expire and physicians willing to use the medication off label can become a less expensive way to get the already approved drug to patients.
I have observed the FDA get involved in clinical trials, with findings that the drug had too many side effects and was not only taken off the market in the U.S., but the smaller study shut down, the researcher put out of business, involved in years of lawsuits, in spite of the temporary benefit to the Alzheimer's patient. Not a cure, but a return of cognition. Too bad.
In Re:
William K. Summers, M.D., is an independent neuroscientist and was the inventor of Tacrine (Cognex) as a treatment for Alzheimer's disease {US Patent No. 4,816,456}. Tacrine was the first FDA approved anti-dementia drug.
"The other question that arises: Did Pfizer choose not to pursue a clinical trial due to the fact that Enbrel’s patent would soon be expiring? Enbrel’s 20-year patent has since ended, making way for generic versions of the drug. This means there was no financial incentive for Pfizer to pursue a long, costly clinical trial when profits from the drug would soon shrink to a trickle."
No. When one patent expires, you tweak the formula, change the name, resubmit for approval, take out a new patent and Bob's your uncle - ker-ching again until the next time. It's such a standard strategy, and so easy to align with a radical change of use, that this couldn't possibly have been a significant disincentive.